Cargando…

Diagnosis and clinical severity markers of bullous pemphigoid

The use of a broad spectrum of novel detection systems for autoantibodies to the basement membrane proteins BP180 and BP230 has greatly facilitated the diagnosis of bullous pemphigoid, which most likely explains its increasing incidence in central Europe. Because the pathogenic relevance of antibodi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Enno, Zillikens, Detlef
Formato: Texto
Lenguaje:English
Publicado: Medicine Reports Ltd 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920699/
https://www.ncbi.nlm.nih.gov/pubmed/20948767
http://dx.doi.org/10.3410/M1-15
_version_ 1782185303231954944
author Schmidt, Enno
Zillikens, Detlef
author_facet Schmidt, Enno
Zillikens, Detlef
author_sort Schmidt, Enno
collection PubMed
description The use of a broad spectrum of novel detection systems for autoantibodies to the basement membrane proteins BP180 and BP230 has greatly facilitated the diagnosis of bullous pemphigoid, which most likely explains its increasing incidence in central Europe. Because the pathogenic relevance of antibodies to human BP180 has been convincingly shown both in vitro and in vivo, repeated testing for these antibodies appears to be helpful in guiding treatment decisions during the course of the disease.
format Text
id pubmed-2920699
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Medicine Reports Ltd
record_format MEDLINE/PubMed
spelling pubmed-29206992010-10-14 Diagnosis and clinical severity markers of bullous pemphigoid Schmidt, Enno Zillikens, Detlef F1000 Med Rep Review Article The use of a broad spectrum of novel detection systems for autoantibodies to the basement membrane proteins BP180 and BP230 has greatly facilitated the diagnosis of bullous pemphigoid, which most likely explains its increasing incidence in central Europe. Because the pathogenic relevance of antibodies to human BP180 has been convincingly shown both in vitro and in vivo, repeated testing for these antibodies appears to be helpful in guiding treatment decisions during the course of the disease. Medicine Reports Ltd 2009-02-24 /pmc/articles/PMC2920699/ /pubmed/20948767 http://dx.doi.org/10.3410/M1-15 Text en © 2009 Medicine Reports Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes
spellingShingle Review Article
Schmidt, Enno
Zillikens, Detlef
Diagnosis and clinical severity markers of bullous pemphigoid
title Diagnosis and clinical severity markers of bullous pemphigoid
title_full Diagnosis and clinical severity markers of bullous pemphigoid
title_fullStr Diagnosis and clinical severity markers of bullous pemphigoid
title_full_unstemmed Diagnosis and clinical severity markers of bullous pemphigoid
title_short Diagnosis and clinical severity markers of bullous pemphigoid
title_sort diagnosis and clinical severity markers of bullous pemphigoid
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920699/
https://www.ncbi.nlm.nih.gov/pubmed/20948767
http://dx.doi.org/10.3410/M1-15
work_keys_str_mv AT schmidtenno diagnosisandclinicalseveritymarkersofbullouspemphigoid
AT zillikensdetlef diagnosisandclinicalseveritymarkersofbullouspemphigoid